Top

Published in:

Open Access 01-12-2023 | Multiple Sclerosis | Research

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod

Authors: Alicia Gonzalez-Martinez, Rohit Patel, Brian C. Healy, Hrishikesh Lokhande, Anu Paul, Shrishti Saxena, Mariann Polgar-Turcsanyi, Howard L. Weiner, Tanuja Chitnis

Published in: Journal of Neuroinflammation | Issue 1/2023

Abstract

Background

Multiple sclerosis (MS) is a disabling autoimmune demyelinating disorder affecting young people and causing significant disability. In the last decade, different microRNA (miRNA) expression patterns have been associated to several treatment response therapies such as interferon and glatiramer acetate. Nowadays, there is increasing interest in the potential role of miRNA as treatment response biomarkers to the most recent oral and intravenous treatments. In this study, we aimed to evaluate serum miRNAs as biomarkers of No Evidence of Disease Activity (NEDA-3) at 2 years in patients with relapsing remitting MS (RRMS) treated with fingolimod.

Main body

A Discovery cohort of 31 RRMS patients treated with fingolimod were identified from the CLIMB study and classified as No Evidence of Disease Activity (NEDA-3) or Evidence of Disease Activity (EDA-3) after 2 years on treatment. Levels of miRNA expression were measured at 6 months using human serum miRNA panels and compared in EDA-3 and NEDA-3 groups using the Wilcoxon rank sum test. A set of differentially expressed miRNA was further validated in an independent cohort of 22 fingolimod-treated patients. We found that 548a-3p serum levels were higher levels in fingolimod-treated patients classified as NEDA-3, compared to the EDA-3 group in both the Discovery (n = 31; p = 0.04) and Validation (n = 22; p = 0.03) cohorts 6 months after treatment initiation; miR-548a-3p provided an AUC of 0.882 discriminating patients with NEDA-3 at 2 years in the Validation cohort.

Conclusion

Our results show differences in miR-548a-3p expression at 6 months after fingolimod start in patients with MS with NEDA-3 at 2 years. These results provide class III evidence of the use of miR-548a-3p as biomarker of NEDA-3 in patients with fingolimod.

Available only for authorised users

McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7. https://doi.org/10.1002/ana.1032.CrossRefPubMed

Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292–303. https://doi.org/10.1016/S1474-4422(15)00393-2.CrossRefPubMedPubMedCentral

Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99–110. https://doi.org/10.1038/nrg2936.CrossRefPubMed

Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8. https://doi.org/10.1073/pnas.0804549105.CrossRefPubMedPubMedCentral

Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. https://doi.org/10.1038/cr.2008.282.CrossRefPubMed

Guerau-de-Arellano M, Alder H, Ozer HG, Lovett-Racke A, Racke MK. miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol. 2012;248(1–2):32–9. https://doi.org/10.1016/j.jneuroim.2011.10.006.CrossRefPubMed

Regev K, Paul A, Healy B, et al. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e267. https://doi.org/10.1212/NXI.0000000000000267.CrossRefPubMedPubMedCentral

Regev K, Healy BC, Paul A, et al. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e491. https://doi.org/10.1212/NXI.0000000000000491.CrossRefPubMedPubMedCentral

Hemond CC, Healy BC, Tauhid S, et al. MRI phenotypes in MS: longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019;6(2):e530. https://doi.org/10.1212/NXI.0000000000000530.CrossRefPubMedPubMedCentral

10.

Paul A, Comabella M, Gandhi R. Biomarkers in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9(3): a029058. https://doi.org/10.1101/cshperspect.a029058.CrossRefPubMedPubMedCentral

11.

Ehtesham N, Mosallaei M, Karimzadeh MR, Moradikazerouni H, Sharifi M. microRNAs: key modulators of disease-modifying therapies in multiple sclerosis. Int Rev Immunol. 2020;39(6):264–79. https://doi.org/10.1080/08830185.2020.1779712.CrossRefPubMed

12.

Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015;43(Web server issue):W460–6. https://doi.org/10.1093/nar/gkv403.CrossRefPubMedPubMedCentral

13.

Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999;27(1):29–34. https://doi.org/10.1093/nar/27.1.29.CrossRefPubMedPubMedCentral

14.

Saxena S, Lokhande H, Gombolay G, Raheja R, Rooney T, Chitnis T. Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases. Sci Rep. 2020;10:12405. https://doi.org/10.1038/s41598-020-69182-w.CrossRefPubMedPubMedCentral

15.

Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36. https://doi.org/10.1148/radiology.143.1.7063747.CrossRefPubMed

16.

Harrell FE Jr. Regression modeling strategies. New York: Springer; 2006.

17.

Wang Y, Zheng F, Gao G, et al. MiR-548a-3p regulates inflammatory response via TLR4/NF-κB signaling pathway in rheumatoid arthritis. J Cell Biochem. 2018. https://doi.org/10.1002/jcb.26659.CrossRefPubMedPubMedCentral

18.

Zhao X, Li R, Qiao M, Yan J, Sun Q. MiR-548a-3p promotes keratinocyte proliferation targeting PPP3R1 after being induced by IL-22. Inflammation. 2018;41(2):496–504. https://doi.org/10.1007/s10753-017-0705-3.CrossRefPubMed

19.

Motaei J, Kerachian MA, Mousavi SA, et al. Circulating miR-455-3p, miR-5787, and miR-548a-3p as potential noninvasive biomarkers in the diagnosis of acute graft-versus-host disease: a validation study. Ann Hematol. 2021;100(10):2621–31. https://doi.org/10.1007/s00277-021-04573-1.CrossRefPubMed

20.

Shim SM, Jung SY, Nam HY, et al. Network signatures of cellular immortalization in human lymphoblastoid cell lines. Biochem Biophys Res Commun. 2013;441(2):438–46. https://doi.org/10.1016/j.bbrc.2013.10.081.CrossRefPubMed

21.

Herrmann MM, Barth S, Greve B, Schumann KM, Bartels A, Weissert R. Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Dis Model Mech. 2016;9(10):1211–20. https://doi.org/10.1242/dmm.025536.CrossRefPubMedPubMedCentral

22.

Nuñez-Borque E, Fernandez-Bravo S, Rodriguez Del Rio P, et al. Increased miR-21-3p and miR-487b-3p serum levels during anaphylactic reaction in food allergic children. Pediatr Allergy Immunol. 2021;32(6):1296–306. https://doi.org/10.1111/pai.13518.CrossRefPubMedPubMedCentral

23.

Li X, Lou X, Xu S, Du J, Wu J. Hypoxia inducible factor-1 (HIF-1α) reduced inflammation in spinal cord injury via miR-380-3p/ NLRP3 by Circ 0001723. Biol Res. 2020;53(1):35. https://doi.org/10.1186/s40659-020-00302-6.CrossRefPubMedPubMedCentral

24.

Tetik Vardarlı A, Düzgün Z, Erdem C, Kaymaz BT, Eroglu Z, Çetintas VB. Matrine induced G0/G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia (T-ALL) cells. Bosn J Basic Med Sci. 2018;18(2):141–9. https://doi.org/10.17305/bjbms.2017.2457.CrossRefPubMed

25.

Gnanakkumaar P, Murugesan R, Ahmed SSSJ. Gene regulatory networks in peripheral mononuclear cells reveals critical regulatory modules and regulators of multiple sclerosis. Sci Rep. 2019;9(1):12732. https://doi.org/10.1038/s41598-019-49124-x.CrossRefPubMedPubMedCentral

26.

Ebrahimkhani S, Beadnall HN, Wang C, et al. Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment. Mol Neurobiol. 2020;57(2):1245–58. https://doi.org/10.1007/s12035-019-01792-6.CrossRefPubMed

27.

Fenoglio C, Riz MD, Pietroboni AM, et al. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. J Neuroimmunol. 2016;299:81–3. https://doi.org/10.1016/j.jneuroim.2016.08.017.CrossRefPubMed

28.

Boffa G, Bruschi N, Cellerino M, et al. Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population. CNS Drugs. 2020;34(4):425–32. https://doi.org/10.1007/s40263-020-00714-8.CrossRefPubMed

29.

Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, et al. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients. CNS Neurosci Ther. 2018;24(12):1175–84. https://doi.org/10.1111/cns.12851.CrossRefPubMedPubMedCentral

Title: miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
Authors: Alicia Gonzalez-Martinez
Rohit Patel
Brian C. Healy
Hrishikesh Lokhande
Anu Paul
Shrishti Saxena
Mariann Polgar-Turcsanyi
Howard L. Weiner
Tanuja Chitnis
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Multiple Sclerosis
Fingolimod
Biomarkers
Published in: Journal of Neuroinflammation / Issue 1/2023
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-023-02811-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod

Abstract

Background

Main body

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Main body

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Cortistatin deficiency reveals a dysfunctional brain endothelium with impaired gene pathways, exacerbated immune activation, and disrupted barrier integrity

IL-10 production by granulocytes promotes Staphylococcus aureus craniotomy infection

Contribution of macrophages to neural survival and intracochlear tissue remodeling responses following cochlear implantation

Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis

TNFR1 signaling converging on FGF14 controls neuronal hyperactivity and sickness behavior in experimental cerebral malaria

Age- and sex-related differences of periodontal bone resorption, cognitive function, and immune state in APP/PS1 murine model of Alzheimer’s disease